📈
7×
GHR Upregulation
Growth hormone receptor by day 3
Healing & Recovery
BPC-157
★★★★★4.6 (195)
BepecinBPC-15PL 14736Gastric Pentadecapeptide BPC
Body Protection Compound - Research peptide for tissue repair studies
Dosage
$--
Quantity
1
Free shipping
60-day guarantee
Secure checkout
We accept
Free shipping
on orders over $150
on orders over $150
60-day money-back
guarantee
guarantee
Secure checkout
256-bit SSL
256-bit SSL
Certificate of Analysis
Third Party Tested
Latest selected dosage
99%+
Purity
Variant: BPC-157
Lot #: Current batch
Click to view full size
✅
7/12
Human Patients
Reported pain relief >6 months
📚
200+
Publications
Peer-reviewed studies since 1991
🛡️
No LD50
Achieved
No lethal dose found in toxicity studies
⏱️
14-21 days
Typical Timeline
For observable effects in studies
How BPC-157 Works
The science, simplified
Multi-Pathway Healing Mechanism
BPC-157 works through several interconnected biological pathways that promote healing and tissue repair. It activates cellular repair mechanisms, supports blood vessel formation, and modulates inflammation.
VEGF
Primary
VEGFR2 Pathway
- Promotes new blood vessel formation
- Increases blood flow to injured areas
- Activates endothelial cell proliferation
NO
Modulatory
Nitric Oxide System
- Dilates blood vessels
- Improves oxygen delivery
- Protects against ischemia
GF
Supportive
Growth Factor Pathways
- Enables cell migration to injury sites
- Promotes cell survival and growth
- Activates tissue repair genes
Key mechanism
VEGFR2-Akt-eNOS Signaling Cascade
BPC-157 activates the VEGFR2 pathway, promoting receptor internalization and downstream signaling. This triggers the Akt-eNOS cascade and increased nitric oxide production in preclinical models.
VEGFR2 Expression↑ Upregulated
Receptor Internalization↑ Enhanced
Akt Phosphorylation↑ Time-dependent
eNOS Activation↑ Increased NO
Growth pathway
GHR Upregulation & Tissue Repair
Preclinical findings report increased Growth Hormone Receptor (GHR) expression and enhanced migration-related signaling in tissue-repair models.
GHR Expression (Day 3)7× increase
FAK Phosphorylation↑ Dose-dependent
Paxillin Activation↑ Enhanced
Cell Migration↑ 70% faster
2025 Systematic Review (36 Studies)
7/12
Patients reported pain relief >6 months (only human study)
Tendon Fibroblast Outgrowth95%
Cell Migration (Wound Healing)90%
Cell Survival Under Stress85%
VEGFR2 Expression88%
Key outcomes
Research Success Metrics
58%
Pain relief >6 months
Human knee study (n=12)
100%
No toxicity observed
All preclinical studies
92%
Positive outcomes
In musculoskeletal models
Preclinical Evidence
Accelerated Wound Closure95%
Increased Blood Vessel Formation88%
Enhanced Cell Migration90%
Reduced Inflammation82%
Healing Time Reduction
Tendon Transection50%
Rat Achilles model
Skin Wound Closure45%
Alkali burn model
Muscle Crush Injury40%
Rat quadriceps
Research Applications
Tendon
Healing
Enhanced fibroblast outgrowth and collagen synthesis
J Applied Physiology
GI Tract
Protection
Stable in gastric juice for 24+ hours
Gut and Liver Journal
Neuro
Protection
Brain injury and dopamine/serotonin modulation studied
Curr Neuropharmacology
Bone
Healing
Enhanced bone defect healing in rabbit studies
J Orthop Research
Dosing Information from Research
BPC-157 has been administered via multiple routes in research settings. Most animal studies use μg/kg or ng/kg dosing, while the Phase 1 human trial tested oral tablets.
Human clinical trial
Phase 1 Clinical Trial (NCT02637284)
- • 1mg, 3mg, or 6mg oral tablet
- • Three times daily × 14 days in one arm
- • Status: Completed (2016)
Preclinical research
Preclinical Dosing (Animal Studies)
- • 10 μg/kg common range
- • 10 ng/kg ultra-low dose reported
- • 500 μg/kg safety range reported